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Almost 100 years ago, Theodor Boveri, working with sea urchin
embryos containing aberrant numbers of spindle poles,
observed that the progeny produced contained abnormal num-
bers of chromosomes, a condition described as aneuploidy
(Boveri, 1914). At that time it was already well known that aneu-
ploidy was a common characteristic of tumors, and Boveri pro-
posed that aneuploid progeny produced from a disrupted
mitosis become the progenitor cells of tumors. This original
hypothesis remains untested. Nevertheless, a link between
mitosis, aneuploidy, and cancer has been widely assumed.
Contrary to its potential for initiating tumorigenesis, mitosis
has also served as a successful antitumor target. Indeed, drugs
that arrest cells in mitosis, known as antimitotics, are common
treatments for a variety of human tumors, including breast,
ovarian, and non-small-cell lung cancer. However, the mecha-
nism linking long-term mitotic arrest to cell death has remained
almost completely unexplored.The paper published in this issue
by Tao and colleagues (Tao et al., 2005) represents some of the
first evidence on the clinically relevant linkage between mitotic
arrest, the mitotic checkpoint whose action is responsible for
that arrest, and cell death. In light of this evidence, we review
here what is currently known about the mitotic checkpoint and
its role in tumorigenesis and cell death, and highlight some of
the fundamental questions that remain unanswered.
The mitotic checkpoint:The primary defense against 
aneuploidy
The mitotic checkpoint, also known as the spindle assembly
checkpoint, is the major cell cycle control mechanism in mitosis.
It is responsible for the production of genetically identical
daughter cells by ensuring accurate chromosome segregation.
Proper chromosome segregation requires that one copy of each
pair of replicated sister chromatids be delivered to each daugh-
ter cell. This is accomplished by organizing the sister chro-
matids on a bipolar mitotic spindle composed of microtubules
(Figure 1). The chromosomes connect to spindle microtubules
through their kinetochores, protein-rich structures that assem-
ble and disassemble every mitosis at sites of centromeric DNA,
located at the primary constriction of the chromosome.
Unattached kinetochores generate diffusible checkpoint com-
plexes that comprise a “wait anaphase” signal, which delays the
irreversible process of sister chromatid separation until each
and every kinetochore has become productively attached to the
mitotic spindle. This ensures the faithful segregation of sister
chromatids and the prevention of aneuploidy.
At a molecular level, the mitotic checkpoint prevents
advance to anaphase by producing an inhibitor(s) of the
anaphase-promoting complex (APC). The APC is an E3 ubiqui-
tin ligase which ubiquitinates mitotic substrates whose subse-
quent proteosome-mediated destruction is necessary for
anaphase onset. APC inhibition is accomplished by recruiting
checkpoint proteins, including Bub1, BubR1, Bub3, Mad1, and
Mad2 to unattached kinetochores (Figure 2A). There, they are
converted into one or more inhibitors of Cdc20, the specificity
factor that APC requires to recognize mitotic substrates, includ-
ing securin and cyclin B. The identity of the in vivo inhibitor(s)
remains unknown, but may include activated forms of Mad2 or
BubR1, or a complex of Cdc20, Mad2, BubR1, and Bub3
(Figures 1B and 2A) (Fang, 2002; Fang et al., 1998; Sudakin et
al., 2001; Tang et al., 2001). After all kinetochores have properly
attached (metaphase; Figure 1C), signal generation is silenced
and the APCCdc20 inhibitors decay through an ill-defined mecha-
nism that may include the action of the Mad2 binding factor
Cmt2 (Habu et al., 2002). APCCdc20-mediated ubiquitination of
securin leads to activation of its binding partner separase,
which cleaves the cohesins that maintain the linkage between
sister chromatids, leading to sister chromatid separation and
anaphase onset (Figure 1D). Ubiquitination and degradation of
cyclin B inactivates Cdk1, thereby permitting exit from mitosis
(reviewed in Wasch and Engelbert, 2005). In this fashion, the
mitotic checkpoint prevents aneuploidy by permitting unat-
tached kinetochores on chromosomes that would be missegre-
gated to delay the irreversible transition from metaphase to
anaphase until they become appropriately attached.
The mitotic checkpoint was initially recognized 15 years ago
in experiments using antimitotic drugs that depolymerize micro-
tubules (Hoyt et al., 1991; Li and Murray, 1991). These micro-
tubule poisons cause all kinetochores to become unattached
and, therefore, a maximal mitotic checkpoint signal is generat-
ed. In the succeeding years, testing for the ability to arrest in
response to microtubule poisons has been commonly used as
the sole test for checkpoint competence.This approach fueled a
view still held by some that the checkpoint is either “on” or “off,”
depending on whether or not cells accumulate in mitosis in
response to spindle disruption. This view is incorrect. The pri-
mary role of the mitotic checkpoint is to protect against misseg-
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regation of single chromosomes, a role that requires the ability
to produce a robust checkpoint response in the presence of
even a single unattached kinetochore.
Genetic evidence has now demonstrated that cells with
weakened checkpoint machinery cannot prevent single chromo-
somes from being missegregated during an otherwise unper-
turbed mitosis, although they can and do arrest when all
kinetochores are signaling after spindle disruption. For exam-
ple, cells with diminished levels of CENP-I/Mis6 (Liu et al.,
2003), Aurora B (Ditchfield et al., 2003; Hauf et al., 2003),
CENP-E (Weaver et al., 2003), Bub1 (Johnson et al., 2004), or
the adenomatous polyposis coli gene (Fodde et al., 2001;
Kaplan et al., 2001), which is frequency mutated in colon can-
cers, arrest in response to microtubule depolymerization, but
produce aneuploid progeny due to missegregation of one or a
few chromosomes per division. The molecular mechanism of
this differential checkpoint response has been investigated in
four of these five examples. In each case, the signals of two or
more essential kinetochore proteins were diminished, but not
eliminated. While complete mislocalization or deletion of an
essential checkpoint component leads to an inactive check-
point, partial loss or mislocalization of these components leads
to weakened signal generation at individual unattached kineto-
chores (Figure 2C). Thus, cells that recruit suboptimal levels of
checkpoint proteins to kinetochores need larger numbers of
unattached kinetochores to create the threshold of inhibitor nec-
essary to block anaphase onset.
Mitotic checkpoint inactivation is lethal: A weakened
checkpoint generates chromosomal instability
It has long been recognized that missegregation of large num-
bers of chromosomes results in rapid cell death (Boveri,
1914), and it is self-evident that a minimum number of genes
and/or chromosomes must be required for viability. More
recently, mitotic checkpoint genes have been shown to be
required for viability in flies (Basu et al., 1999) and mice
(Baker et al., 2004; Dobles et al., 2000; Kalitsis et al., 2000;
Wang et al., 2004), presumably due to chromosome missegre-
gation. Moreover, direct evidence has emerged from two
groups that the mitotic checkpoint is absolutely essential for
viability in vertebrates (Kops et al., 2004; Michel et al., 2004).
Cells (including human cancer cells exhibiting chromosomal
instability) in which the mitotic checkpoint is completely inacti-
vated by siRNA-mediated depletion of Mad2 or BubR1 speed
through prometaphase and missegregate large numbers of
chromosomes during the subsequent premature anaphase
(Kops et al., 2004; Meraldi et al., 2004; Michel et al., 2004).
This results in rapid cell death that is dependent on chromo-
some loss: Mad2- or BubR1-depleted cells that do not under-
go cytokinesis remain viable through continued cycles of DNA
replication up to at least 32N (Kops et al., 2004; Michel et al.,
2004).
On the other hand, cells and organisms with a weakened
checkpoint remain viable. Mice heterozygous for essential
checkpoint genes are viable and fertile, but have an increased
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Figure 1. The stages of mitosis
Chromosomes enter mitosis as pairs of replicat-
ed sister chromatids that are linked by proteins
known as cohesins. 
A: The chromatids condense during prophase
and are released into the cytoplasm by nuclear
envelope breakdown, which marks the transi-
tion into prometaphase and also represents the
first irreversible transition into mitosis. 
B: During prometaphase, the initially unat-
tached chromatids make connections to the
microtubules of the mitotic spindle and the
mitotic checkpoint is active, which means that
the kinetochores assembled at the centromeres
of unattached chromosomes generate a dif-
fusible wait anaphase inhibitor. Antimitotic
drugs delay cells in prometaphase by produc-
ing unattached kinetochores. 
C: At metaphase, every chromosome has
made proper attachments to the mitotic spin-
dle and has congressed to a central position.
Production of the diffusible wait anaphase
inhibitor has been silenced by stable kineto-
chore-microtubule interactions. As the check-
point inhibitors decay, the anaphase promoting
complex (APC), an E3 ubiquitin ligase, becomes
active and recognizes securin and cyclin B, pro-
voking their degradation. 
D: Loss of securin activates the protease, sepa-
rase, that cleaves the cohesins, triggering sister
chromatid separation and chromosome segre-
gation during anaphase A. 
E: At anaphase B, the spindle elongates.
F: At telophase, the now segregated chromo-
somes begin decondensing and the nuclear
envelopes reform. 
G: Cytokinesis separates the nuclei into two
daughter cells that re-enter interphase.
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frequency of aneuploidy (Baker et al., 2004; Babu et al., 2003;
Dai et al., 2004; Michel et al., 2001; Putkey et al., 2002). The
usual number of chromosomes in these aneuploid cells is actu-
ally quite close to diploid (±4), with ±1 being the most common
karyotype, indicating that these aneuploid cells most likely arose
from the missegregation of only one or a few chromosomes due
to a weakened checkpoint. Thus, a completely inactive check-
point results in cell autonomous lethality, but cells with a weak-
ened checkpoint survive and exhibit chromosomal instability.
Tumors are associated with weakened mitotic checkpoints
All of the evidence obtained to date linking tumorigenesis with the
mitotic checkpoint implicates a weakened mitotic checkpoint in
the transformation process. Mice with a weakened checkpoint
due to heterozygous loss of Mad2 (Michel
et al., 2001) or hypomorphic alleles of
BubR1 (Baker et al., 2004) develop spon-
taneous tumors with enhanced frequency
(27% and 6%, respectively), and mice
heterozygous for Bub3 (Babu et al., 2003)
or BubR1 (Dai et al., 2004) exhibit elevat-
ed rates of tumorigenesis when treated
with carcinogen (70% in Bub3 heterozy-
gotes versus 50% in wild-type and 11% in
BubR1 heterzygote versus 0.4% in wild-
type). BubR1 heterozygosity also acceler-
ates intestinal tumor formation and
progression in ApcMin/+ mice, which form
colon tumors by 3 months of age (Rao et
al., 2005).
In human cancers, a report of heterozygous point mutations
in the Bub1 and BubR1 genes in 2 of 19 colorectal cancer cell
lines (Cahill et al., 1998) stimulated a broad search for muta-
tions in mitotic checkpoint genes in a variety of tumors and
tumor cell lines. Recently, a small number of human patients
have been identified with the rare recessive disorder mosaic
variegated aneuploidy (MVA), which is characterized by an
increase in aneuploidy (>25% of cells exhibit near-diploid aneu-
ploidy) and childhood cancers (Hanks et al., 2004). Five of eight
MVA patients were found to have mutations in both alleles of the
BubR1 gene. One allele contained a mutation giving rise to a
truncated or absent product, while the second allele carried a
missense mutation in either the Cdc20 binding domain or in the
essential kinase (Mao et al., 2003; Tang et al., 2001). However,
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Figure 2. Mitotic checkpoint signaling
A: Unattached kinetochores are the signal gen-
erators of the mitotic checkpoint. They recruit
mitotic checkpoint proteins, including Mad1,
Mad2, BubR1, and Bub3, and convert them into
inhibitors of APCCdc20. 
B: Once all kinetochores have made produc-
tive attachments to spindle microtubules, pro-
duction of the APCCdc20 inhibitors is silenced. 
C: Unattached kinetochores assembled from
mutated components or in the presence of
lower concentrations of checkpoint proteins
generate a weakened mitotic checkpoint sig-
nal and produce fewer APCCdc20 inhibitors.
Figure 3. Spindle defects produced by antimitotic drug treatments
A: The normal bipolar spindle of an untreated cell at metaphase. 
B: Taxol-stabilized microtubules produce multipolar spindles. 
C: Monastrol, a KSP/Eg5 inhibitor, prevents spindle pole separation, resulting in monopolar spindles. 
D: Vinblastine depolymerizes microtubules, preventing spindle assembly. 
E: Cells that have undergone adaptation exit from mitosis despite the continued presence of antimitotic drugs and assemble abnormal interphase nuclei
after aberrant mitotic exit without cytokinesis.
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strikingly few mutations in mitotic checkpoint genes have been
found in other human cancers, though altered transcription of
checkpoint genes may be more common (Wang et al., 2000).
What has been found as a frequent feature of human tumor
cells and cell lines is the inability to sustain mitotic checkpoint sig-
naling, as judged by a reduced mitotic index after long-term drug-
mediated spindle disruption. While this outcome has been
alternately reported as reflecting a checkpoint that is “defective”
(Wang et al., 2000) or “robust” (Tighe et al., 2001), in all of these
cases, a checkpoint signal is produced but not sustained.The uni-
fying message is that many tumors and tumor cell lines, including
chromosomally unstable ones, have a weakened checkpoint sig-
nal that is sufficient for maintaining a viable population of cells but
allows them to missegregate small numbers of chromosomes per
division, resulting in aneuploidy and chromosomal instability.
Chronic activation of the mitotic checkpoint is a common
chemotherapeutic strategy
The taxanes (paclitaxel/taxol, docetaxel), and vinca alkaloids
(vinblastine, vincristine) have been used in the treatment of
human cancer for decades. However, their mechanism of antitu-
mor action remains unresolved. Taxanes stabilize microtubules,
inducing multipolar spindles (Figure 3B), while the vinca alka-
loids inhibit microtubule assembly (Figure 3D). Both types of
drugs cause cells to accumulate in prometaphase as a conse-
quence of mitotic checkpoint signaling from unattached kineto-
chores. However, the length of time for which intracellular drug
concentrations persist at levels sufficient to sustain a check-
point response remains an unanswered question. Additionally,
though it has long been known that continuous treatment with
such microtubule poisons often ultimately leads to cell death,
the mechanism coupling mitotic delay to subsequent death
remains almost completely unexplored.
Possible outcomes of chemotherapeutic activation of the
mitotic checkpoint are outlined in Figure 4. The most obvious
possibility of short-term drug treatment is sustained mitotic
arrest until the drug is cleared. This mechanism of action would
be cytostatic, with renewed cell cycling after drug removal. A
second outcome is known as adaptation
(Rieder and Maiato, 2004), in which cells
exit long-term mitotic arrest while still in
the presence of drug, fail cytokinesis, and
enter G1 (Figure 3E). Whether or not
mitotic checkpoint silencing is a prerequi-
site of adaptation is currently unknown.
Adapted cells could then continue divid-
ing (Figure 4, Adaptation I,), senesce
(Adaptation II), or execute a death path-
way (Adaptation II or III). Tao et al. (2005) now provide sugges-
tive evidence for Adaptation III, in which cells escape to G1
despite continued mitotic checkpoint signaling, and the inappro-
priate presence of elevated levels of checkpoint inhibitors pro-
vokes apoptotic death in interphase. A final possibility is
execution of a death pathway directly from mitosis.
The recent work by Tao and colleagues (2005) brings mitot-
ic arrest and its linkage to cell death to the fore. The authors
report the discovery of KSPIA, a novel small-molecule inhibitor
of KSP (also known as Eg5), a member of the kinesin family of
microtubule-dependent motors. KSP activity is required for spin-
dle pole separation, and inhibition of its ATP-dependent motor
activity results in monopolar spindles with unattached kineto-
chores (Figure 3C). Other KSP inhibitors (Kapoor et al., 2000;
Sakowicz et al., 2004) have previously been reported, and one
(ispinesib, produced by Cytokinetics) is currently being evaluat-
ed in Phase I and II clinical trials. Theoretically, KSP inhibitors
have an advantage over the taxanes and vinca alkaloids in that
KSP apparently functions only in mitosis, so this class of anti
mitotic drug may reduce the unwanted side effects of micro-
tubule disruption, especially in neurons.
Although the effect of KSP inhibitors on microtubules is dif-
ferent from the taxanes and vinca alkaloids, all three classes of
drugs lead to chronic activation of the mitotic checkpoint. Tao et
al. (2005) present some of the first evidence indicating that cell
death following such long-term arrest is mediated by caspase-
dependent death accompanied by activation of Bax, cleavage
of PARP, and activation of the “executioner” caspase-3. Since
treatment with the pancaspase inhibitor zVAD efficiently pre-
vents KSPIA-induced cell death, these results offer strong sup-
port for the hypothesis that apoptotic cell death is induced by
KSP inhibitors.
Tao and colleagues also offer suggestive evidence that cells
treated with taxol or KSPIA exit to G1 before undergoing apop-
tosis (Figure 4, Adaptation III). They find that cells that can sus-
tain a long-term (>48 hr) arrest in mitosis (e.g., HT29 colorectal
adenocarcinoma cells) are less susceptible to KSPIA and taxol-
mediated killing than are cells that more rapidly adapt into G1
M I N I R E V I E W
Figure 4. Possible outcomes of prolonged treat-
ment with antimitotic drugs
Long-term treatment with spindle poisons
(including microtubule depolymerizers, stabiliz-
ers, or KSP/Eg5 inhibitors) can have several out-
comes: (1) chronic arrest in mitosis until the drug
is removed; (24) adaptation from mitosis into
G1 without cytokinesis despite the continued
presence of drug, leading to tetraploidy and (2)
continued cycling, (3) senescence, or (3 and 4)
apoptosis; and (5) death directly from mitosis.
Ispinesib, a KSP inhibitor produced by
Cytokinetics (South San Francisco, CA), is cur-
rently in phase II clinical trials.
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after less than 24 hr in either drug (e.g., HCT116 colorectal car-
cinoma cells). Moreover, cell death is induced in a substantial
number (about 25%) of the KSPIA-resistant HT29 cells by treat-
ing mitotically arrested cells with the Cdk1 inhibitor purvalanol,
which presumably drives the cells out of mitosis.This lends sup-
port to the idea that cells arrested in mitosis must undergo
adaptation in order to execute apoptosis. Observation of adap-
tation and/or apoptotic activation is now needed in live cells
treated with antimitotic drugs to provide a direct test of this
hypothesis.
Based on their indirect evidence, Tao and colleagues pro-
pose that it is the presence of high levels of checkpoint com-
plexes during G1 that triggers apoptosis in cells that have
undergone adaptation (Figure 4, Adaptation III). This sugges-
tion is an attractive idea, but one that now remains to be put to
an experimental test. Is the mechanism of adaptation through
overriding an activated checkpoint signal, or through attenua-
tion of its signaling? A third possibility that is not mutually exclu-
sive with either of the others is that that long-term checkpoint
activation may result in the production and accumulation of a
currently unidentified proapoptotic complex, which may or may
not include checkpoint proteins themselves. Further studies are
now eagerly anticipated to identify the molecular links between
the mitotic checkpoint and the apoptotic cascade.
In the meantime, another question of clinical significance is
whether chromosomally unstable cells are more or less sensi-
tive to antimitotic drug induced cell death, since chromosomal
instability is such a common characteristic of tumor cells. The
limited data now available are contradictory on this point, and
the evidence reported by Tao et al. is no exception. As intro-
duced above, some cells that can sustain prolonged checkpoint
signaling (HT29 cells) are resistant to both taxol and KSPIA-
mediated killing. However, cells with a weakened checkpoint
(either by expression in HeLa cells of a dominant fragment of
Bub1 or heterozygous deletion of Mad2 in HCT 116 cells) are
also less sensitive than normal controls to KSPIA-induced cell
death, even though in the presence of the drug they exit mitosis
more quickly than those controls.This latter example also raises
the possibility that there is a minimal window of time during
which cells must remain arrested in mitosis in order to effective-
ly activate the apoptotic machinery. With the data now available,
no unifying mechanistic conclusion is yet possible, and further
efforts will be required to determine whether chromosomally
unstable cancers with a weakened mitotic checkpoint are more
or less suitable for treatment with antimitotic drugs.
Similarly, the link between the mitotic checkpoint and the
apoptotic machinery remains unclear. What proteins initiate the
signal transduction cascade leading to cell death? Do check-
point proteins participate directly? How long must the cells be
delayed in mitosis in order to trigger apoptosis? What deter-
mines which cells will activate an apoptotic pathway in response
to antimitotic treatment? Moreover, in an example of the “glass
half full or half empty” conundrum, even in the best of circum-
stances reported by Tao et al., approximately 50% of cells
escaped apoptosis after treatment with KSPIA. Such cells
would be predicted to survive chemotherapeutic treatment and
repopulate the tumor in between drug doses, and could there-
fore be argued to be the most problematic. Perhaps by dissect-
ing the molecular linkage between mitotic arrest and cell death,
it may be possible to manipulate insensitive cells in order to pro-
duce a more desirable outcome.
What is clear, especially with the new evidence from Tao et
al., is that there are connections between the mitotic check-
point, aneuploidy, adaptation, and cancer. In all cases, weak-
ened mitotic checkpoint signaling promises to be dangerous,
both in driving tumorigenesis and, possibly, by promoting resis-
tance to chemotherapy. New insights that focus on the molecu-
lar links between mitotic checkpoint activation and the apoptotic
machinery are now needed, if we are to rationally improve the
therapeutic targeting of mitosis.
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